Journal Article

Probiotic Lactobacillus casei Shirota prevents acute liver injury by reshaping the gut microbiota to alleviate excessive inflammation and metabolic disorders

Lv, Longxian, Yan, Ren, Wang, Qiangqiang, Du, Yiling, Jiang, Huiyong, Lu, Yingfeng, Zhang, Hua, Wang, Kaicen, Chen, Lifeng, Li, Lanjuan, Su, Xiaoling, Chen, Xiaoxiao

2022

نظرة عامة

Summary Millions of people die from liver diseases annually, and liver failure is one of the three major outcomes of liver disease. The gut microbiota plays a crucial role in liver diseases. This study aimed to explore the effects of Lactobacillus casei strain Shirota (LcS), a probiotics used widely around the world, on acute liver injury (ALI), as well as the underlying mechanism. Sprague Dawley rats were intragastrically administered LcS suspensions or placebo once daily for 7 days before induction of ALI by intraperitoneal injection of D‐galactosamine (D‐GalN). Histopathological examination and assessments of liver biochemical markers, inflammatory cytokines, and the gut microbiota, metabolome and transcriptome were conducted. Our results showed that pretreatment with LcS reduced hepatic and intestinal damage and reduced the elevation of serum gamma‐glutamyltranspeptidase (GGT), total bile acids, IL‐5, IL‐10, G‐CSF and RANTES. The analysis of the gut microbiota, metabolome and transcriptome showed that LcS lowered the ratio of Firmicutes to Bacteroidetes; reduced the enrichment of metabolites such as chenodeoxycholic acid, deoxycholic acid, lithocholic acid, d‐talose and N‐acetyl‐glucosamine, reduce the depletion of d‐glucose and l‐methionine; and alleviated the downregulation of retinol metabolism and PPAR signalling and the upregulation of the pyruvate metabolism pathway in the liver. These results indicate the promising prospect of using LcS for the treatment of liver diseases, particularly ALI. The aim of this study is to evaluate the effect of pretreatment with the probiotic Lactobacillus casei Shirota (LcS) on acute liver injury (ALI) in rats. LcS administration ameliorates ALI‐related organ damage, alleviating inflammatory status and metabolic disorders. Furthermore, the LcS‐reshaped gut microbiota is shown to modulate liver injury‐related signalling pathways and enterohepatic cross‐talk. These findings support the use of LcS as a promising functional food additive in liver disease treatments.

• الناشر: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• موضوع: Animals / Bile acids / Biochemical markers / Chenodeoxycholic acid / Cytokines / D-Galactosamine / Deoxycholic acid / Depletion / Digestive system / Discriminant analysis / Gastrointestinal Microbiome / Gastrointestinal tract / Glucosamine / Gut microbiota / Inflammation / Injury prevention / Intestinal microflora / Lactobacilli / Lactobacillus casei / Liver / Liver diseases / Liver failure / Metabolic Diseases / Metabolic disorders / Metabolism / Metabolites / Methionine / Microbiota / Peroxisome proliferator-activated receptors / Probiotics / Pyruvic acid / RANTES / Rats / Rats, Sprague-Dawley / Signal transduction / Small intestine / Substance abuse treatment / Transcriptomes / Vitamin A